<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855709</url>
  </required_header>
  <id_info>
    <org_study_id>bacterial resistence</org_study_id>
    <nct_id>NCT03855709</nct_id>
  </id_info>
  <brief_title>Antibiotic-resistant Bacterial Infection of Hepatic Patients</brief_title>
  <official_title>Patterns of Antibiotic Resistant Bacterial Infections in Liver Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <brief_summary>
    <textblock>
      the investigators want to identify the microbial profile, antibiotic resistant bacteria in
      hepatic patients with infections in Liver ICU, and explore risk factors and outcomes in those
      patients with antibiotic resistant bacteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial infection signifies major clinical challenge in cirrhotic patients where about 35%
      of these patients acquire hospital-acquired infections compared with 5% of other hospital
      in-patients without cirrhosis.It is associated with a mortality rate of 38% with a four-fold
      increase compared to individuals without cirrhosis.

      Cirrhotic patients have a high risk for antimicrobial resistance because of chronic use of
      prescribed antibiotics like quinolones in secondary prophylaxis for spontaneous bacterial
      peritonitis. In addition, undergoing invasive procedures and recurrent hospital admissions
      encourage both increased occurrence of antimicrobial resistance and the spread of resistant
      pathogens in these patients.

      Epidemiology, risk factors and clinical outcomes of MDR infections have raised a special
      attention in cirrhosis. Some studies reported bacterial resistance in about 50% of examined
      patients and it is associated with treatment failure, septic shock and hospital mortality
      especially in nosocomial and healthcare related infections
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of different bacterial causing infections in hepatic patients</measure>
    <time_frame>baseline</time_frame>
    <description>Bacteriological cultures will be performed with VITEK 2 COMPACT-15 automated system (bioMerieux Inc, Mercy L'etoil, Fransa).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To detect antibiotic resistant bacteria among these patients.</measure>
    <time_frame>baseline</time_frame>
    <description>molecular detection of genes responsible for antibiotic resistance using PCR for isolates bacteria</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Antibiotic Resistant Infection</condition>
  <condition>Liver Cirrhoses</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>microbiological culture and sensetivity</intervention_name>
    <description>microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients diagnosed to have ESLD admitted to EL-Rajhi liver hsopital (Assiut university
        hopsitals) diagnosed to have infection at admission or develop infection during
        hospitalization
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ESLD at Liver ICU. All patients have the diagnostic criteria for liver
             cirrhosis by clinical, biochemical, and ultrasonography findings. The severity of
             liver cirrhosis will be assessed according to the Child-Pugh classification and model
             for end-stage liver disease (MELD) score.

          -  These patients are diagnosed as having infection at admission or acquire infection
             during hospitalization.

        Exclusion Criteria:

          -  Age ≤ 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karema Azoz Mostafa</last_name>
    <phone>+201018494961</phone>
    <email>karimaazoz89@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012 May;55(5):1551-61. doi: 10.1002/hep.25532. Epub 2012 Apr 4.</citation>
    <PMID>22183941</PMID>
  </reference>
  <reference>
    <citation>Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002 Jan;35(1):140-8.</citation>
    <PMID>11786970</PMID>
  </reference>
  <reference>
    <citation>Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5. doi: 10.1053/j.gastro.2010.06.019. Epub 2010 Jun 14.</citation>
    <PMID>20558165</PMID>
  </reference>
  <reference>
    <citation>Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, Lattanzi B, Giusto M, Ceccarelli G, Farcomeni A, Riggio O, Venditti M. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PLoS One. 2015 May 21;10(5):e0127448. doi: 10.1371/journal.pone.0127448. eCollection 2015.</citation>
    <PMID>25996499</PMID>
  </reference>
  <reference>
    <citation>Merli M, Lucidi C. Bacterial resistance in cirrhotic patients: an emerging reality. J Hepatol. 2012 Apr;56(4):756-7. doi: 10.1016/j.jhep.2011.12.004. Epub 2012 Jan 8.</citation>
    <PMID>22230869</PMID>
  </reference>
  <reference>
    <citation>Shallcross L, O'Brien A. Antimicrobial resistance in liver disease: better diagnostics are needed. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):151-153. doi: 10.1016/S2468-1253(16)30240-0. Epub 2017 Feb 9.</citation>
    <PMID>28404125</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Karema Azoz Mostafa</investigator_full_name>
    <investigator_title>Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

